source
- Avalo scores Phase 2 success in comeback bid, raises $375MAvalo Therapeutics’ comeback bid surged forward Tuesday afternoon, as the immunology biotech secured a mid-stage trial win in an inflammatory skin disorder. Avalo said that both doses of an experim…Endpoints · 3mo ago↗ source
- STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human diseaseAn international team has found thousands of mini-proteins, including some involved in cell division and DNA repair, as well as several unique to cancer cells.STAT · 3mo ago↗ source
- Avalo shares spike on skin drug data; BioNTech to cut staffAvalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.